Estrella Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2024	FY 2023	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '21 Dec 31, 2021
Cash & Equivalents	1.93	1.38	0.92	4.17	2.48	0.48
Short-Term Investments	-	-	-	-	-	45.19
Cash & Short-Term Investments	1.93	1.38	0.92	4.17	2.48	45.67
Cash Growth	357.30%	50.97%	-77.99%	68.02%	-94.57%	-
Other Receivables	-	-	-	-	0.27	-
Total Trade Receivables	-	-	-	-	0.27	-
Other Current Assets	0.23	0.29	0.72	0.29	-	0.14
Total Current Assets	2.16	1.68	1.64	4.45	2.75	0.62
Other Long-Term Assets	1.5	1.5	1.5	-	0.28	-
Total Assets	3.66	3.18	3.14	4.45	3.03	45.8
Accounts Payable	0.01	0.55	0	-	9.33	0
Accrued Expenses	8.27	12.39	2.79	0	0.02	-
Other Current Liabilities	0.64	0.59	0.21	0.18	0.4	0.07
Total Current Liabilities	8.93	13.54	3	0.18	9.76	0.07
Other Long-Term Liabilities	-	-	-	-	0.01	1.55
Total Long-Term Liabilities	-	-	-	-	0.01	1.55
Total Liabilities	8.93	13.54	3	0.18	9.77	1.62
Preferred Stock	-	-	-	-	5	-
Common Stock	0	0	0	0	0	0
Treasury Stock	-0.6	-0.6	-0.57	-0.35	-	-
Additional Paid-in Capital	34.61	27.22	24.64	24.12	0.45	-
Retained Earnings	-39.28	-36.99	-23.93	-19.5	-12.19	-1.01
Total Common Shareholders' Equity	-5.27	-10.37	0.14	4.27	-6.74	-1.01
Minority Interest	-	-	-	-	-	45.19
Shareholders' Equity	-5.27	-10.37	0.14	4.27	-6.74	44.18
Total Liabilities & Equity	3.66	3.18	3.14	4.45	3.03	45.8
Net Cash (Debt)	1.93	1.38	0.92	4.17	2.48	45.67
Net Cash Growth	39.23%	50.97%	-77.99%	68.02%	-94.57%	-
Net Cash Per Share	0.05	0.04	0.03	0.15	1.75	38.72
Book Value	-5.27	-10.37	0.14	4.27	-6.74	-1.01
Book Value Per Share	-0.14	-0.28	0.00	0.16	-4.75	-0.85
Tangible Book Value	-5.27	-10.37	0.14	4.27	-6.74	-1.01
Tangible Book Value Per Share	-0.14	-0.28	0.00	0.16	-4.75	-0.85

SEC Filings: 10-K · 10-Q